IERAMILIMAB

UNII:	OI8P0SFD4R
Formula:
Preferred Substance Name:	IERAMILIMAB

2137049-37-5
ANTI-LAG-3 MONOCLONAL ANTIBODY LAG525
HUMANISED IMP-701
IERAMILIMAB [INN]
IERAMILIMAB [USAN]
IERAMILIMAB [WHO-DD]
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS LAG3 (LYMPHOCYTE ACTIVATING 3, LYMPHOCYTE-ACTIVATION 3, CD223)), HUMANIZED MONOCLONAL ANTIBODY; GAMMA4 HEAVY CHAIN HUMANIZED (1-451) (VH (HOMO SAPIENS IGHV7-4-1*02 (85.7%)-(IGHD)-IGHJ4*01 (92.3%)) (8.8.18) (1-125)-HOMO SAPIENS IGHG4*01 (CH1 (126-223), HINGE S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K2>DEL (451)) (126-451)), (139-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-214') (V-KAPPA (HOMO SAPIENS IGVK1-33*01 (83.2%)-IGKJ1*01 (100%)) (6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')); DIMER (231-231'':234-234'')-BISDISULFIDE
LAG525
LAG-525
NVP-LAG525

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

IERAMILIMAB

Synonyms and Mappings

Resources